2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products

Code: 
2100

Most active institutional investors by number of deals

Pages

Selected funding rounds

Date Company Profile Round
Oct 2011 Azelon Pharmaceuticals Inc Series A
Sep 2011 Orphazyme ApS Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases. Series A
Sep 2011 Crescendo Bioscience Inc Series C
Sep 2011 Orphazyme ApS Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases. Series A
Sep 2011 SironRx Therapeutics Inc Develops regenerative therapies for the treatment of dermal wound repair Series A
Sep 2011 Orphazyme ApS Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases. Series A
Aug 2011 Affinium Pharmaceuticals Ltd Developing a novel class of antibiotics. N/A
Aug 2011 SironRx Therapeutics Inc Develops regenerative therapies for the treatment of dermal wound repair Series A
Aug 2011 SironRx Therapeutics Inc Develops regenerative therapies for the treatment of dermal wound repair Series A
Aug 2011 SironRx Therapeutics Inc Develops regenerative therapies for the treatment of dermal wound repair Series A
Aug 2011 Affinium Pharmaceuticals Ltd Developing a novel class of antibiotics. N/A
Aug 2011 Verinata Health Inc Series C
Aug 2011 Affinium Pharmaceuticals Ltd Developing a novel class of antibiotics. N/A
Jul 2011 Roka Bioscience Inc Series C
28 Jun 2011 Nimbus Discovery LLC A computational technology-based drug discovery company. Series A
28 Jun 2011 Nimbus Discovery LLC A computational technology-based drug discovery company. Series A
Jun 2011 Aegea Medical Inc AEGEA Medical, Inc. develops and sells medical devices for treatment of abnormal uterine bleeding. Series B
Jun 2011 Revance Therapeutics Inc Develops and commercializes therapeutic products for treating chronic disease and age-related changes to skin and soft tissue. Venture
Jun 2011 Revance Therapeutics Inc Develops and commercializes therapeutic products for treating chronic disease and age-related changes to skin and soft tissue. Venture
Jun 2011 Regenesis Biomedical Inc Series C

Pages

Selected companies

Company type: 
Drug discovery company committed to the development of breakthrough medicines for the treatment of cancer.
Company type: 
Biopharmaceutical company committed to improving the lives of patients worldwide.
Company type: 
Advanced fight against drug resistant microbes by attacking novel targets with novel drugs.
Company type: 
Engages in the identification and development of prescription drugs
Company type: 
A drug discovery and development company focused on delivering breakthrough treatments in neurological disorders
Company type: 
Biopharmaceutical company developing small molecule therapeutics that target ion channels for treatment of a variety of diseases.
Company type: 
Innovative drug discovery and development company.
Subscribe to RSS - 2100 Manufacture of pharmaceuticals, medicinal chemical and botanical products